Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data

Pharmacology and Therapeutics

Volumn 129, Issue 2, 2011, Pages 185-194

  Ma, Terry K W ^a   Yan, Bryan P ^a   Lam, Yat Yin ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dabigatran; Direct thrombin inhibitor; Efficacy; Safety

Indexed keywords

DABIGATRAN ETEXILATE;

BLEEDING; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBIN TIME; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; HUMANS; PYRIDINES; STROKE; THROMBIN; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 79251593748     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.09.005     Document Type: Review

References (55)

1. G.W. Albers, H.C. Diener, L. Frison, M. Grind, M. Nevinson, and S. Partridge Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 6 2005 690 698
2. F.A. Anderson Jr., and F.A. Spencer Risk factors for venous thromboembolism Circulation 107 23 Suppl 1 2003 I9 I16
3. F.A. Anderson Jr., H.B. Wheeler, R.J. Goldberg, D.W. Hosmer, N.A. Patwardhan, and B. Jovanovic A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study Arch Intern Med 151 5 1991 933 938
4. S.M. Bates, and J.I. Weitz The mechanism of action of thrombin inhibitors J Invasive Cardiol 12 2000 Suppl F: 27F-32
5. R.C. Becker Cell-based models of coagulation: a paradigm in evolution J Thromb Thrombolysis 20 1 2005 65 68
6. S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos 36 2 2008 386 399
7. W. Bode The structure of thrombin, a chameleon-like proteinase J Thromb Haemost 3 11 2005 2379 2388
8. M. Burns Management of narrow therapeutic index drugs J Thromb Thrombolysis 7 2 1999 137 143
9. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
10. J.T. Crawley, S. Zanardelli, C.K. Chion, and D.A. Lane The central role of thrombin in hemostasis J Thromb Haemost 5 Suppl 1 2007 95 101
11. S. El Rouby, C.A. Mestres, F.M. LaDuca, and M.L. Zucker Racial and ethnic differences in warfarin response J Heart Valve Dis 13 1 2004 15 21
12. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 26 2008 2765 2775
13. B.I. Eriksson, O.E. Dahl, L. Ahnfelt, P. Kälebo, J. Stangier, and G. Nehmiz Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I J Thromb Haemost 2 9 2004 1573 1580
14. B.I. Eriksson, O.E. Dahl, H.R. Büller, R. Hettiarachchi, N. Rosencher, and M.L. Bravo A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial J Thromb Haemost 3 1 2005 103 111
15. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 9591 2007 949 956
16. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 11 2007 2178 2185
17. M.D. Ezekowitz, P.A. Reilly, G. Nehmiz, T.A. Simmers, R. Nagarakanti, and K. Parcham-Azad Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol 100 9 2007 1419 1426
18. R.J. Friedman, O.E. Dahl, N. Rosencher, J.A. Caprini, A.A. Kurth, and C.W. Francis Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials Thromb Res 126 3 2010 164 165
19. V. Fuster, L.E. Rydén, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 7 2006 e257 e354
20. C. Galle, J.P. Papazyan, M.J. Miron, D. Slosman, H. Bounameaux, and A. Perrier Prediction of pulmonary embolism extent by clinical findings, D-dimer level and deep vein thrombosis shown by ultrasound Thromb Haemost 86 5 2001 1156 1160
21. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 1 2010 15 20
22. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 6 Suppl 2008 381S 453S
23. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 7 1999 492 501
24. J.A. Heit Venous thromboembolism epidemiology: implications for prevention and management Semin Thromb Hemost 2002 Suppl 2 2002 3 13
25. J. Hirsh, V. Fuster, J. Ansell, J.L. Halperin, and American Heart Association/American College of Cardiology Foundation American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J Am Coll Cardiol 41 9 2003 1633 1652
26. M. Hoffman, and D.M. Monroe III A cell-based model of hemostasis Thromb Haemost 85 6 2001 958 965
27. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 9632 2008 31 39
28. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 26 2008 2776 2786
29. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 9717 2010 807 815
30. L.G. Licari, and J.P. Kovacic Thrombin physiology and pathophysiology J Vet Emerg Crit Care San Antonio 19 1 2009 11 22
31. R. Mohapatra, M. Tran, J.M. Gore, and F.A. Spencer A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era Am Heart J 150 1 2005 19 26
32. N. Oake, D.A. Fergusson, A.J. Forster, and C. van Walraven Frequency of adverse events in patients with poor anticoagulation: a meta-analysis CMAJ 176 11 2007 1589 1594
33. S.B. Olsson, and Executive Steering Committee of the SPORTIF III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 9397 2003 1691 1698
34. P. Petersen, M. Grind, J. Adler, and SPORTIF II Investigators Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study J Am Coll Cardiol 41 9 2003 1445 1451
35. A.B. Platt, A.R. Localio, C.M. Brensinger, D.G. Cruess, J.D. Christie, and R. Gross Risk factors for nonadherence to warfarin: results from the IN-RANGE study Pharmacoepidemiol Drug Saf 17 9 2008 853 860
36. RE-MOBILIZE Writing Committee Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 1 2009 1 9
37. A.R. Rudnicka, D. Ashby, P. Brennan, and T. Meade Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect Arch Intern Med 163 12 2003 1454 1460
38. M. Schindewolf, S. Schwaner, M. Wolter, H. Kroll, A. Recke, and R. Kaufmann Incidence and causes of heparin-induced skin lesions CMAJ 181 8 2009 477 481
39. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 24 2009 2342 2352
40. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 5 2008 285 295
41. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, and H. Stähle Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 5 2005 555 563
42. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 3 2007 292 303
43. J. Stangier, H. Stähle, K. Rathgen, and R. Fuhr Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin Pharmacokinet 47 1 2008 47 59
44. B. Subramaniam, and K.W. Park Direct thrombin inhibitors Int Anesthesiol Clin 43 2 2005 39 53
45. L. Testa, F. Andreotti, G.G. Biondi Zoccai, F. Burzotta, F. Bellocci, and F. Crea Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22, 639 patients Int J Cardiol 122 2 2007 117 124
46. A.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 9676 2009 1673 1680
47. C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A.J. Forster Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 5 2006 1155 1166
48. J.I. Weitz, M. Hudoba, D. Massel, J. Maraganore, and J. Hirsh Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Invest 86 2 1990 385 391
49. J.I. Weitz, B. Leslie, and M. Hudoba Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors Circulation 97 6 1998 544 552
50. P.S. Wells, A.M. Holbrook, N.R. Crowther, and J. Hirsh Interactions of warfarin with drugs and food Ann Intern Med 121 9 1994 676 683
51. R.H. White The epidemiology of venous thromboembolism Circulation 17; 107 23 Suppl 1 2003 I4 I8
52. W. Wienen, J.M. Stassen, H. Priepke, U.J. Ries, and N. Hauel In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate Thromb Haemost 98 1 2007 155 162
53. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 1991 983 988
54. S.E. Wolowacz, N.S. Roskell, F. Maciver, S.M. Beard, P.A. Robinson, and J.M. Plumb Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Clin Ther 31 1 2009 194 212
55. S.E. Wolowacz, N.S. Roskell, J.M. Plumb, J.A. Caprini, and B.I. Eriksson Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis Thromb Haemost 101 1 2009 77 85